Long-term Effects of COVID-19

Mayo Clinic

Status: Completed

Conditions: COVID-19; SAR-CoV-2

Treatments: Drug: 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB); Drug: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT05220514

21-008855

R35NS097273 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to measure, monitor, and analyze long term effects of SARS-CoV-2. The main purpose is to assess the post-hospitalization outcomes of patients who were diagnosed with SAR-CoV-2 by comparing to patients who were hospitalized with an acute neurological disease.

Enrollment: 71 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Control Participants: Males and females over the age of 18 years hospitalized and receiving intensive care for diagnosis's other than COVID-19 or an acute neurological disease and who were not diagnosed (clinically or with PCR testing) with COVID-19.
• Case Participants: Males and females over the age of 18 years who had been hospitalized at Mayo Clinic Hospital for treatment of COVID-19 confirmed by PCR test.
• We acknowledge that some participants may be unable to consent due to underlying medical conditions; an eligible proxy may provide the informed consent and provide a signature on the designated line.
• Women of childbearing age, between the ages of 18 to 55, must complete a negative pregnancy test.
• Minority individuals over the age of 18 years will be eligible to enroll.

Exclusion criteria

• Males and females, under the age of 18 years.
• Participants with PET/MRI non-compatible devices.
• Claustrophobia.
• Allergies to study related procedures.
• Pregnant , incarcerated, or institutionalized subjects will not be included in the study.

Trial design

71 participants in 2 patient groups

Non-COVID-19 Diagnosis Control Group

Description:

Subjects hospitalized and receiving intensive care for diagnosis of an acute neurological disease other than COVID-19

Treatment:

Drug: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)

Drug: 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)

COVID-19 Diagnosis Case Group

Description:

Subjects previously hospitalized at Mayo Clinic Hospital for treatment of PCR test confirmed COVID-19

Treatment:

Drug: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)

Drug: 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)